Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide versus placebo in low-risk del(5q) myelodysplastic syndrome without transfusion dependence
2009-013619-36Phase 3Completed
- Sponsor
- Universidad de Salamanca
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in 5q deletion syndrome comparing Revlimid with Placebo (2 arms). Primary endpoints: Time to progression to transfusion dependence and Erythroid response. Started Aug 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
5q deletion syndrome
Beyond the preview
Go deeper on 2009-013619-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013619-36.